Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 25 - Drugs for disorders of the nervous system
Patents for A61P 25 - Drugs for disorders of the nervous system (183,225)
02/2012
02/09/2012WO2012018909A1 Fused heterocyclic compounds
02/09/2012WO2012018790A2 Dual variable domain immunoglobulins and uses thereof
02/09/2012WO2012018704A1 Use of teriflunomide for treating multiple sclerosis
02/09/2012WO2012018635A2 Arylsulfonamide derivatives, compositions, and methods of use
02/09/2012WO2012018257A1 Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
02/09/2012WO2012018069A1 Preparation for treatment of spinal cord injury
02/09/2012WO2012018059A1 Heterocyclic compound
02/09/2012WO2012018058A1 Fused heterocyclic ring compound
02/09/2012WO2012017876A1 P2x4 receptor antagonist
02/09/2012WO2012017663A1 Mononuclear cell separation column, mononuclear cell separation system, method for separating out mononuclear cells, mononuclear cells, and drug for internal administration
02/09/2012WO2012017551A1 Therapeutic agent for disease
02/09/2012WO2012017451A1 A bio-stabilized resveratrol formulation
02/09/2012WO2012017119A2 Non-viral vectors for gene therapy
02/09/2012WO2012016930A1 Compound useful for the treatment of nonsense-mutation-mediated diseases and pharmaceutical composition comprising said compound
02/09/2012WO2012016879A1 Combinations comprising atypical antipsychotics and taar1 agonists
02/09/2012WO2012016708A1 Oral dosage form comprising dimebolin and donepezil
02/09/2012WO2012016707A2 Oral dosage form for the modified release of dimebolin
02/09/2012WO2012016569A1 Deuterated tandospirone derivatives as 5-ht1a receptor agonists
02/09/2012WO2012016362A1 Β-secretase inhibitors for treating alzheimer's disease and uses thereof
02/09/2012WO2012016314A1 Arachidonic acid-derived coxib analogue-substituted compounds for use in treating pain
02/09/2012WO2011156900A3 Compounds, compositions and methods for treatment of multiple sclerosis
02/09/2012WO2011133637A3 Compounds and methods for kinase modulation, and indications therefor
02/09/2012US20120035272 Method to Ameliorate Oxidative Stress and Improve Working Memory Via Pterostilbene Administration
02/09/2012US20120035267 Paracetamol for parenteral adminstration
02/09/2012US20120035264 Use of methionine sulfoximine to treat acute liver failure and other diseases caused by an inflammatory cytokine response
02/09/2012US20120035258 Methods of using prodrugs of pregabalin
02/09/2012US20120035251 Thiophene inhibitors of ikk-b serine-threonine protein kinase
02/09/2012US20120035250 Plasmalogen compounds, pharmaceutical compositions containing the same and methods for treating diseases of the aging
02/09/2012US20120035239 2-oxo-1-pyrrolidine derivatives, processes for preparing them and their uses
02/09/2012US20120035235 Methods of treating alpha adrenergic mediated conditions
02/09/2012US20120035232 Use of angiotensin ii agonists
02/09/2012US20120035231 Specific diarylhydantoin and diarylthiohydantoin compounds
02/09/2012US20120035230 Compounds, Compositions, and Methods for the Treatment of Beta-Amyloid Diseases and Synucleinopathies
02/09/2012US20120035226 Oxadiazole derivatives
02/09/2012US20120035222 Solid forms of 2-Chloro-4-[1-(4-fluoro-phenyl)-2,5-dimethyl-1H-imidazol-4-ylethynyl]-pyridine
02/09/2012US20120035217 Bis Aromatic Compounds for Use as LTC4 Synthase Inhibitors
02/09/2012US20120035214 Renin inhibitors
02/09/2012US20120035210 2,3-dihydrobenzo(1,4) dioxin-2-ylmethyl derivatives as alpha2c antagonists for use in the treatment of peripheric and central nervous systeme diseases
02/09/2012US20120035208 Pyrazolopyridine pi3k inhibitor compounds and methods of use
02/09/2012US20120035207 Use of GABAA Receptor Agonists for the Treatment of Hearing, Vestibular and Attention Disorders, Intention Tremor and Restless Leg Syndrome
02/09/2012US20120035203 Butaclamol for the treatment of amyotrophic lateral sclerosis
02/09/2012US20120035199 Spiroheterocyclic compounds and their uses as therapeutic agents
02/09/2012US20120035197 Novel Use of Fibrates
02/09/2012US20120035194 Substituted 2-amino-fused heterocyclic compounds
02/09/2012US20120035192 Selective antagonists of a2a adenosine receptors
02/09/2012US20120035191 Deuterium-enriched pyrimidine compounds and derivatives
02/09/2012US20120035189 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
02/09/2012US20120035188 Liquid formulations of salts of 1-[2-(2,4-dimethylphenylsulfanyl)phenyl]-piperazine
02/09/2012US20120035187 Anti-neurodegenerative disease agent
02/09/2012US20120035185 Method of Using Flibanserin for Neuroprotection
02/09/2012US20120035182 Methods of treatment of chronic pain using eszopiclone
02/09/2012US20120035179 Modulators of atp-binding cassette transporters
02/09/2012US20120035178 Quinuclidine Compounds as Alpha-7 Nicotinic Acetylcholine Receptor Ligands
02/09/2012US20120035175 Novel salts as Anti-Inflammatory, Immunomodulatory and Anti-Proliferatory Agents
02/09/2012US20120035173 Di-substituted amides for enhancing glutamatergic synaptic responses
02/09/2012US20120035170 Novel unsaturated tetracyclic tetrahydrofuran derivatives
02/09/2012US20120035168 N-((6-amino-pyridin-3-yl)methyl)-heteroaryl-carboxamides
02/09/2012US20120035167 Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors
02/09/2012US20120035164 Chemical compounds
02/09/2012US20120035159 Substituted isoquinoline derivative
02/09/2012US20120035156 Combination of glyt1 compound with antipsychotics
02/09/2012US20120035154 Modulators of Cellular Adhesion
02/09/2012US20120035150 Mif inhibitors and their uses
02/09/2012US20120035149 Prokineticin Receptor Antagonists And Uses Thereof
02/09/2012US20120035140 Carbamoylphosphonates as inhibitors and uses thereof
02/09/2012US20120035139 Gamma-amino-butyric acid derivatives as gabab receptor ligands
02/09/2012US20120035131 Pyrazoline compounds
02/09/2012US20120035120 Glycolipids as treatment for disease
02/09/2012US20120035112 Neuronal differentiation-inducing peptide and use thereof
02/09/2012US20120035102 Azinone-substituted azabicycloalkane-indole and azabicycloalkane-pyrrolo-pyridine mch-1 antagonists, methods of making, and use thereof
02/09/2012US20120035100 Satiation peptide administration
02/09/2012US20120035094 F11 receptor (f11r) antagonists as therapeutic agents
02/09/2012US20120034326 Novel herbal formulation advocated for the prevention and management of coronary heart disease
02/09/2012US20120034324 Role of an herbal formulation in the prevention and management of age related neurodegenerative disorders with special reference to senile dementia
02/09/2012US20120034308 Reduced-cholesterol dairy product for use as a medicament
02/09/2012US20120034306 Polymeric drug delivery systems and processes for producing such systems
02/09/2012US20120034304 Prolonged Release Pharmaceutical Composition Containing 3-(3-Dimethylamino-1-Ethyl-2-Methyl-Propyl)Phenol
02/09/2012US20120034303 Pharmaceutical formulation comprising one or more fumaric acid esters in an erosion matrix
02/09/2012US20120034300 Stabilized zolpidem pharmaceutical compositions
02/09/2012US20120034298 Chewable Soft Capsule
02/09/2012US20120034297 Pharmaceutical dosage forms comprising 6'-fluoro-(N-methyl- or N,N-dimethyl-)-4-phenyl-4',9'-dihydro-3'H-spiro[cyclohexane-1,1'-pyrano[3,4,b]indol]-4-amine
02/09/2012US20120034293 Transdermal delivery of cannabinoids
02/09/2012US20120034274 Pharmaceutical composition comprising one or more fumaric acid esters
02/09/2012US20120034261 Novel immunogenic compositions for the prevention and treatment of meningococcal disease
02/09/2012US20120034245 Single-chain multivalent binding proteins with effector function
02/09/2012US20120034221 T-Cell Receptor Antibodies And Methods of Use Thereof
02/09/2012US20120034205 Pkc activators and anticoagulant in regimen for treating stroke
02/09/2012US20120034201 Composition for regulating lipid metabolism
02/09/2012US20120034195 Placental stem cells derive from post-partum manmalian placenta, and uses and methods of treatment using said cells
02/09/2012US20120034193 Treatment of neurotrophic factor mediated disorders
02/09/2012US20120034171 Abuse-proofed dosage form
02/09/2012US20120034169 Nitric oxide-releasing particles for nitric oxide therapeutics and biomedical applications
02/09/2012US20120034160 Dual variable domain immunoglobulins and uses thereof
02/09/2012US20120034159 Antibodies that bind both bcma and taci
02/09/2012DE102010038842A1 New aptamer that specifically binds to human tau protein or its fragment, useful e.g. in vitro for isolating, purifying and/or detecting tau protein, and to treat cerebral infarction, pick disease and/or progressive supranuclear palsy
02/09/2012DE102010033527A1 Quetiapin-Tabletten Quetiapine tablets
02/09/2012CA2810150A1 P2x4 receptor antagonist
02/09/2012CA2807510A1 Disorders of neuronal connectivity
02/09/2012CA2807224A1 Preparation for treatment of spinal cord injury
02/09/2012CA2807187A1 Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
1 ... 258 259 260 261 262 263 264 265 266 267 268 269 270 271 272 273 274 275 276 277 278 ... 1833